News Focus
News Focus
Followers 28
Posts 2529
Boards Moderated 0
Alias Born 05/08/2015

Re: StealthGold post# 195455

Thursday, 12/02/2021 7:27:29 AM

Thursday, December 02, 2021 7:27:29 AM

Post# of 236489
Ummm...the DATA IS DEFINITELY THERE as everyone can clearly see. The interim results are FANTASTIC and there are NO OTHER drugs that come close to treating NASH like LL. And BTW, Sidley is their attorney, not their Chief Medical Officer.

Note the change in tone from seeking BTD for NASH to seeking FTD for NASH. Even NP (probably at Sidley's nudging) said that they will no longer seek BTD for NASH - why? The data is not there.


"Leronlimab open label NASH results continue to show reductions in fat and fibrosis suggestive of a potential therapy not only for NAFLD (Non-Alcoholic Fatty Liver Deposit) but also in NASH. Fat reductions by proton density fat fraction PDFF up to 45% along with reductions in fibrosis up to 8% by CT1 were noted from baseline after just 14 weeks of treatment. The reductions in fibrosis were seen in both severe and mild-moderate NASH cases."

My comments are just my opinions and should NOT be taken as investment advice.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News